Hepatitis Monthly

Published by: Kowsar

The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients

Farah Bokharaei-Salim 1 , 2 , Mostafa Salehi-Vaziri 3 , Farzin Sadeghi 4 , Maryam Esghaei 1 , Seyed Hamidreza Monavari 1 , Seyed Moayed Alavian 5 , 6 , Shahin Fakhim 7 and Hossein Keyvani 1 , *
Authors Information
1 Department of Virology, Iran University of Medical Sciences, Tehran, IR Iran
2 HIV Laboratory of National Center, Deputy of Health, Iran University of Medical Sciences, Tehran, IR Iran
3 Department of Arboviruses and Viral Hemorrhagic Fevers (National Ref Lab), Pasteur Institute of Iran, Tehran, IR Iran
4 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran
5 Middle East Liver Disease Center, Tehran, IR Iran
6 Iran Hepatitis Network, Tehran, IR Iran
7 Department of Civil Engineering, Faculty of Engineering, Payame Noor University, Karaj, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2016, 16 (5); e35597
  • Published Online: April 23, 2016
  • Article Type: Research Article
  • Received: December 18, 2015
  • Revised: March 23, 2016
  • Accepted: April 12, 2016
  • DOI: 10.5812/hepatmon.35597

To Cite: Bokharaei-Salim F, Salehi-Vaziri M, Sadeghi F, Esghaei M, Monavari S H, et al. The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients, Hepat Mon. 2016 ; 16(5):e35597. doi: 10.5812/hepatmon.35597.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Bokharaei Salim F, Keyvani H, Amiri A, Jahanbakhsh Sefidi F, Shakeri R, Zamani F. Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol. 2010; 16(16): 2005-9[PubMed]
  • 2. Sakamoto N, Watanabe M. New therapeutic approaches to hepatitis C virus. J Gastroenterol. 2009; 44(7): 643-9[DOI][PubMed]
  • 3. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010; 30(8): 1173-80[DOI][PubMed]
  • 4. Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Nasseri S. Distribution of hepatitis C virus genotypes among azerbaijani patients in capital city of iran-tehran. Hepat Mon. 2013; 13(9)[DOI][PubMed]
  • 5. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9): 1259-69[DOI][PubMed]
  • 6. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007; 46(1): 37-47[DOI][PubMed]
  • 7. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut. 2004; 53(9): 1345-51[DOI][PubMed]
  • 8. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005; 48(6): 372-80[DOI][PubMed]
  • 9. Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis. 1997; 29(1): 17-22[PubMed]
  • 10. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int. 2009; 29 Suppl 1: 15-8[DOI][PubMed]
  • 11. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007; 46(3): 403-10[DOI][PubMed]
  • 12. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009; 81(3): 452-8[DOI][PubMed]
  • 13. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007; 50(5): 361-8[DOI][PubMed]
  • 14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 15. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 16. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10): 1100-4[DOI][PubMed]
  • 17. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45[DOI][PubMed]
  • 18. Bokharaei-Salim F, Keyvani H, Salehi-Vaziri M, Sadeghi F, Monavari SH, Mehrnoush L, et al. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNalpha-2a/RBV combination therapy in Azerbaijani patients. Arch Virol. 2014; 159(11): 2893-9[DOI][PubMed]
  • 19. Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S, et al. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNalpha-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol. 2014; 86(9): 1499-506[DOI][PubMed]
  • 20. Li S, Hu P, Zhang QQ, Liu YH, Hu HD, Zhang DZ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon. 2011; 11(3): 163-72[PubMed]
  • 21. Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN, et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol. 2011; 83(6): 989-95[DOI][PubMed]
  • 22. Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M. Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 1996; 7(1): 7-16[PubMed]
  • 23. Alestig E, Arnholm B, Eilard A, Lagging M, Nilsson S, Norkrans G, et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis. 2011; 11: 124[DOI][PubMed]
  • 24. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011; 54(4): 716-22[DOI][PubMed]
  • 25. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y, et al. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat. 2006; 13(9): 582-90[DOI][PubMed]
  • 26. Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008; 27(1): 72-9[DOI][PubMed]
  • 27. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 28. Hoffmann L, Ramos JA, Souza EV, Araujo Ramos AL, Villela-Nogueira CA, Urmenyi TP, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J. 2013; 10: 57[DOI][PubMed]
  • 29. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006; 78(1): 83-90[DOI][PubMed]
  • 30. Kurbanov F, Tanaka Y, Matsuura K, Sugauchi F, Elkady A, Khan A, et al. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. J Infect Dis. 2010; 201(11): 1663-71[DOI][PubMed]
  • 31. Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, et al. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology. 2003; 124(5): 1465-75[PubMed]
  • 32. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003; 17(3): 488-90[DOI][PubMed]
  • 33. Melen K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol. 2004; 73(4): 536-47[DOI][PubMed]
  • 34. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003; 4(1): 63-8[DOI][PubMed]
  • 35. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine. 2005; 31(2): 109-18[DOI][PubMed]
  • 36. Par A, Par G, Tornai I, Szalay F, Varszegi D, Frater E, et al. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Res Notes. 2014; 7: 12[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments